Alina Danu

577 total citations
38 papers, 377 citations indexed

About

Alina Danu is a scholar working on Pathology and Forensic Medicine, Oncology and Hematology. According to data from OpenAlex, Alina Danu has authored 38 papers receiving a total of 377 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pathology and Forensic Medicine, 24 papers in Oncology and 9 papers in Hematology. Recurrent topics in Alina Danu's work include Lymphoma Diagnosis and Treatment (24 papers), CAR-T cell therapy research (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Alina Danu is often cited by papers focused on Lymphoma Diagnosis and Treatment (24 papers), CAR-T cell therapy research (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Alina Danu collaborates with scholars based in France, United States and Belgium. Alina Danu's co-authors include Vincent Ribrag, Jean‐Marie Michot, Julien Lazarovici, David Ghez, Aurélien Marabelle, Romain‐David Seban, Roch Houot, Laurent Dercle, Lawrence H. Schwartz and Samy Ammari and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Alina Danu

34 papers receiving 372 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alina Danu France	10	246	169	104	70	49	38	377
Juan Pinelli United States	5	331 1.3×	161 1.0×	76 0.7×	74 1.1×	38 0.8×	8	655
Brian Hess United States	11	452 1.8×	354 2.1×	122 1.2×	115 1.6×	47 1.0×	53	597
Hong Cen China	8	128 0.5×	119 0.7×	72 0.7×	58 0.8×	22 0.4×	16	348
Wenbin Qian China	12	144 0.6×	112 0.7×	51 0.5×	56 0.8×	16 0.3×	40	310
Aleš Obr Czechia	8	384 1.6×	366 2.2×	74 0.7×	80 1.1×	43 0.9×	21	483
Sandra P. Susanibar-Adaniya United States	7	172 0.7×	137 0.8×	52 0.5×	31 0.4×	21 0.4×	28	332
Filippo Venturini Italy	9	182 0.7×	198 1.2×	93 0.9×	23 0.3×	27 0.6×	25	341
Huiqiang Huang China	11	236 1.0×	185 1.1×	145 1.4×	11 0.2×	28 0.6×	27	389
Honghui Huang China	14	123 0.5×	114 0.7×	63 0.6×	54 0.8×	31 0.6×	37	471

Countries citing papers authored by Alina Danu

Since Specialization

Citations

This map shows the geographic impact of Alina Danu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alina Danu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alina Danu more than expected).

Fields of papers citing papers by Alina Danu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alina Danu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alina Danu. The network helps show where Alina Danu may publish in the future.

Co-authorship network of co-authors of Alina Danu

This figure shows the co-authorship network connecting the top 25 collaborators of Alina Danu. A scholar is included among the top collaborators of Alina Danu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alina Danu. Alina Danu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pagès, Arnaud, Rudy Birsen, Adrien Contejean, et al.. (2024). Venetoclax–proteasome inhibitor–dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm. Blood Advances. 9(4). 793–796. 2 indexed citations

Morice, Pierre‐Marie, Marion Sassier, Véronique Lelong‐Boulouard, et al.. (2024). Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO’s pharmacovigilance database. Blood Cancer Journal. 14(1). 177–177. 1 indexed citations

Lazarovici, Julien, et al.. (2023). Incidence, characteristics, management and outcome of patients with follicular lymphoma with tumor epidural compression, a study on 22 cases. Cancer/Radiothérapie. 27(5). 370–375. 1 indexed citations

Willekens, Christophe, Claude Chahine, Camille Bigenwald, et al.. (2023). When monoclonal gammopathy‐associated chronic neutrophilic leukemia is a reactive process distinct from a clonal myeloproliferative neoplasm: Lessons from mistakes. SHILAP Revista de lepidopterología. 4(3). 823–826. 2 indexed citations

Michot, Jean‐Marie, Maxime Annereau, Alina Danu, et al.. (2021). Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma. Cancer Drug Resistance. 4(3). 710–718. 3 indexed citations

Lünemann, Anna, Simone Bürgler, Alina Danu, et al.. (2021). Reduced frequency of cytotoxic CD56dim CD16+ NK cells leads to impaired antibody-dependent degranulation in EBV-positive classical Hodgkin lymphoma. Cancer Immunology Immunotherapy. 71(1). 13–24. 10 indexed citations

Quivoron, Cyril, Jean‐Marie Michot, Valérie Camara‐Clayette, et al.. (2020). 66P High incidence of TP53 and epigenetic modifying oncogene mutations in a large cohort of patients enrolled in phase I clinical trials for R/R DLBCL. Annals of Oncology. 31. S1237–S1237. 1 indexed citations

Adam, Julien, Pauline Gravelle, Virginie Marty, et al.. (2020). Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 21(4). 257–266.e3. 41 indexed citations

Rassy, Elie, Alina Danu, Tony Ibrahim, et al.. (2020). Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience. Clinical Lymphoma Myeloma & Leukemia. 21(4). e373–e380. 5 indexed citations

10.

Assi, Tarek, Alina Danu, Christine Mateus, et al.. (2019). Post-Shingles Granulomatous Dermatosis Related to Anti-Programmed Cell Death 1. Immunotherapy. 11(7). 591–598. 6 indexed citations

11.

Michot, Jean‐Marie, Maxime Annereau, Alina Danu, et al.. (2019). High‐dose cyclophosphamide for hard‐to‐treat patients with relapsed or refractory B‐cell non‐Hodgkin's lymphoma, a phase II result. European Journal Of Haematology. 104(4). 281–290. 6 indexed citations

12.

Dercle, Laurent, Samy Ammari, Romain‐David Seban, et al.. (2018). Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma. European Journal of Cancer. 91. 136–144. 27 indexed citations

13.

Michot, Jean‐Marie, Julien Lazarovici, Khalil Saleh, et al.. (2017). Dose-Adjusted Rituximab Mini-CYVE (CYtarabine bolus, VEpeside and dexamethasone) for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Not Eligible for High Dose Therapy. Blood. 130. 2847–2847.

14.

Dercle, Laurent, Romain‐David Seban, Julien Lazarovici, et al.. (2017). ¹⁸F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti–Programmed Death 1 Immune Checkpoint Inhibitor. Journal of Nuclear Medicine. 59(1). 15–24. 89 indexed citations

15.

Turpin, Anthony, Jean‐Marie Michot, Emmanuelle Kempf, et al.. (2017). Le lymphome de Hodgkin : stratégies thérapeutiques actuelles et futures. Bulletin du Cancer. 105(1). 81–98. 3 indexed citations

16.

Terroir, M., Julia Arfi‐Rouche, Jean‐Marie Michot, et al.. (2017). Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma. European Journal of Nuclear Medicine and Molecular Imaging. 44(12). 2018–2024. 21 indexed citations

17.

Michot, Jean‐Marie, Julien Lazarovici, David Ghez, et al.. (2017). Challenges and perspectives in the immunotherapy of Hodgkin lymphoma. European Journal of Cancer. 85. 67–77. 20 indexed citations

18.

Annereau, Maxime, Christophe Willekens, Claude Chahine, et al.. (2017). Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease. Leukemia Research. 55. 58–64. 7 indexed citations

19.

Ghez, David, Alina Danu, & Vincent Ribrag. (2015). Investigational drugs for T-cell lymphoma. Expert Opinion on Investigational Drugs. 25(2). 171–181. 1 indexed citations

20.

Danu, Alina, Vincent Ribrag, Stéphane de Botton, et al.. (2012). Un diagnostic qui aura pris du temps. La Revue de Médecine Interne. 34(1). 57–60. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact